NCT05885698 MYLUNG Consortium Part 3: Observational Study
| NCT ID | NCT05885698 |
| Status | Recruiting |
| Phase | — |
| Sponsor | US Oncology Research |
| Condition | Carcinoma, Non-Small-Cell Lung |
| Study Type | OBSERVATIONAL |
| Enrollment | 7,500 participants |
| Start Date | 2023-01-30 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 7,500 participants in total. It began in 2023-01-30 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.
Eligibility Criteria
Inclusion Criteria: * Adult subjects (18 years and older) with newly diagnosed early stage, locally advanced or metastatic non-small cell lung cancer * Must be eligible for systemic therapy based on the treating provider's assessment. If systemic therapy was recommended and documented by the treating provider but the patient declined, they can still be eligible for the study. Patients can be enrolled prior to start of treatment. * Subjects who developed locally advanced or metastatic disease after receiving adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of locally advanced or metastatic disease * Subjects must be enrolled within 30 days of initiation of systemic therapy * Signed informed consent Exclusion Criteria: * Stage IA at the time of enrollment * Subjects with small cell lung cancer * Subjects with Unknown primary tumor origin
Contact & Investigator
Makenzi C. Evangelist, MD
PRINCIPAL INVESTIGATOR
New York Oncology Hematology
Frequently Asked Questions
Who can join the NCT05885698 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Carcinoma, Non-Small-Cell Lung. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05885698 currently recruiting?
Yes, NCT05885698 is actively recruiting participants. Contact the research team at andrea.glidden@mckesson.com for enrollment information.
Where is the NCT05885698 trial being conducted?
This trial is being conducted at Daphne, United States, Prescott Valley, United States, Denver, United States, Palm Bay, United States and 11 additional locations.
Who is sponsoring the NCT05885698 clinical trial?
NCT05885698 is sponsored by US Oncology Research. The principal investigator is Makenzi C. Evangelist, MD at New York Oncology Hematology. The trial plans to enroll 7,500 participants.